Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study

Open access
Santema, Bernadet T, Ouwerkerk, Wouter, Tromp, Jasper, Sama, Iziah E, Ravera, Alice, Regitz-Zagrosek, Vera, Hillege, Hans, Samani, Nilesh J, Zannad, Faiez, Dickstein, Kenneth, Lang, Chim C, Cleland, John G, Ter Maaten, Jozine M, Metra, Marco, Anker, Stefan D, van der Harst, Pim, Ng, Leong L, van der Meer, Peter, van Veldhuisen, Dirk J, Meyer, Sven, Lam, Carolyn S P, Richards, Arthur Mark, Lam, Carolyn S.P., Anand, Inder, Hung, Chung-Lieh, Ling, Lieng Hsi, Liew, Houng Bang, Narasimhan, Calambur, Ngarmukos, Tachapong, Park, Sang Weon, Reyes, Eugenio, Siswanto, Bambang Budi, Shimizu, Wataru, Zhang, Shu, Voors, Adriaan A·2019·The Lancet

Abstract

BACKGROUND Guideline-recommended doses of angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), and β blockers are similar for men and women with heart failure with reduced ejection fraction (HFrEF), even though there are known sex differences in pharmacokinetics of these drugs. We hypothesised that there might be sex differences in the optimal dose of ACE inhibitors or ARBs and β blockers in patients with HFrEF. METHODS We did a post-hoc analysis of BIOSTAT-CHF, a prospective study in 11 European countries of patients with heart failure in whom initiation and up-titration of ACE inhibitors or ARBs and β blockers was encouraged by protocol. We included only patients with left ventricular ejection fraction less than 40%, and excluded those who died within the first 3 months. Primary outcome was a composite of time to all-cause mortality or hospitalisation for heart failure. Findings were validated in ASIAN-HF, an independent cohort of 3539 men and 961 women with HFrEF. FINDINGS Among 1308 men and 402 women with HFrEF from BIOSTAT-CHF, women were older (74 [12] years vs 70 [12] years, p<0·0001) and had lower bodyweights (72 [16] kg vs 85 [18] kg, p<0·0001) and heights (162 [7] cm vs 174 [8] cm, p<0·0001) than did men, although body-mass index did not differ significantly. A similar number of men and women reached guideline-recommended target doses of ACE inhibitors or ARBs (99 [25%] vs 304 [23%], p=0·61) and β blockers (57 [14%] vs 168 [13%], p=0·54). In men, the lowest hazards of death or hospitalisation for heart failure occurred at 100% of the recommended dose of ACE inhibitors or ARBs and β blockers, but women showed approximately 30% lower risk at only 50% of the recommended doses, with no further decrease in risk at higher dose levels. These sex differences were still present after adjusting for clinical covariates, including age and body surface area. In the ASIAN-HF registry, similar patterns were observed for both ACE inhibitors or ARBs and β blockers, with women having approximately 30% lower risk at 50% of the recommended doses, with no further benefit at higher dose levels. INTERPRETATION This study suggests that women with HFrEF might need lower doses of ACE inhibitors or ARBs and β blockers than men, and brings into question what the true optimal medical therapy is for women versus men. FUNDING European Commission.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31792-1

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 258

Metadata

Authors
Santema, B. T., Ouwerkerk, W., Tromp, J., Sama, I. E., Ravera, A., Regitz-Zagrosek, V., Hillege, H., Samani, N. J., Zannad, F., Dickstein, K., Lang, C. C., Cleland, J. G., Ter Maaten, J. M., Metra, M., Anker, S. D., van der Harst, P., Ng, L. L., van der Meer, P., van Veldhuisen, D. J., Meyer, S., Lam, C. S. P., Richards, A. M., Lam, C. S. P., Anand, I., Hung, C.-L., Ling, L. H., Liew, H. B., Narasimhan, C., Ngarmukos, T., Park, S. W., Reyes, E., Siswanto, B. B., Shimizu, W., Zhang, S., & Voors, A. A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-10
Volume
394
Issue
10205
Pages
1254-1263
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2969530388
Cited by
258
References
31
FWCI
19.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31792-1
The paper
Santema, B. T., Ouwerkerk, W., Tromp, J., Sama, I. E., Ravera, A., Regitz-Zagrosek, V., Hillege, H., Samani, N. J., Zannad, F., Dickstein, K., Lang, C. C., Cleland, J. G., Ter Maaten, J. M., Metra, M., Anker, S. D., van der Harst, P., Ng, L. L., van der Meer, P., van Veldhuisen, D. J., . . . Voors, A. A. (2019). Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. The Lancet. https://doi.org/10.1016/s0140-6736(19)31792-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.